Navigation Links
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
Date:5/19/2011

KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

CSL627, a unique single-chain recombinant factor VIII (rFVIII) studied for treatment of hemophilia A, will enter phase I clinical testing.

The structure of factor VIII (FVIII) is based on two linked protein chains—a heavy one and a light one. Under certain conditions, this structure can dissociate, resulting in the formation of separated, or "dissociated," FVIII chains. CSL627 uses a strong, covalent bond that connects the light and heavy chains, thereby creating a single-chain rFVIII.

In-house studies have shown that the molecular integrity of CSL627 is significantly increased using this single-chain design, resulting in a homogenous product that may be more stable than currently available options. In addition, in-vitro studies have shown that CSL627 demonstrates a very strong affinity for von Willebrand factor (VWF) and a faster and more efficient binding to VWF than is demonstrated in wild-type FVIII. The FVIII/VWF complex plays an important role in the physiological activity and clearance of FVIII and has been shown to have an influence on the presentation of FVIII to the immune system.

"For more than 90 years, CSL Behring has been committed to providing safe and effective therapies to help improve the lives of patients and caregivers affected by hemophilia A and other rare bleeding disorders," said  Dr. Andrew Cuthbertson, Chief Scientist, CSL Limited. "Developing innovative therapeutic solutions to se
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
4. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
5. New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
7. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ZIONA, Israel , June 18, 2013 ... complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, ... announced today that the company has been granted a ... indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate Compounds ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/4b8vj2/injectable_drug ) has announced the addition of ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics [Diabetes ... report to their offering. ...
(Date:6/18/2013)... 18, 2013 As a leading ... proudly announces the release of their infographic - ... ". , MeMD's goal was to leverage an ... Health 2.0, Health 3.0 and mHealth.The infographic features ... medical care and the fitness industry in unimaginable ...
Breaking Biology Technology:Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... Cedara Software , a Merge Healthcare developer ... with Ft. Lauderdale-based dental imaging company, i-Dent Imaging ... agreement, Cedara will be an exclusive global channel for ... contacts to promote and market this technology to customers ...
... some buzz rustling around the biz about how gaming is going ... UW-System Advanced Distributed Learning Co-Lab are doing some really ... ,Guess what? Gaming is just the tip of an iceberg big ... shop floor to the boardroom. , ,This is a great ...
... receive a $500,000 grant from the Department of Commerce ... Gateway Manufacturing Technology Center in Eau Claire. Nanotechnology is ... of the atom. , ,"Through this project, we are ... expand, and reach its full potential," said Gov. Jim ...
Cached Biology Technology:Just in time for Christmas: Retail IT. 2Just in time for Christmas: Retail IT. 3
(Date:6/19/2013)... 2013 A decade-long JDRF-funded study led by ... Mnchen, Germany, is providing a deeper understanding of ... developing type 1 diabetes (T1D), highlighting the importance ... disease. The study, "Seroconversion to Multiple Islet Autoantibodies ... was published today in The Journal of ...
(Date:6/19/2013)... NEW YORK , June 19, 2013  New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of scientific, ... to announce the launch of a new open access ... of GeoResJ , Elsevier,s earth and planetary science ... The journal aims to provide a forum for rapid ... field. The journal will be co-edited by six Executive ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... wastewater and generates electricity can also remove 90 percent of ... team of researchers from China and the U.S. Clean ... resource in some parts of the world. Its availability in ... desalinate water using either a reverse osmosis process -- one ...
... global warming from 53 million to 47 million years ago ... western North America, researchers from three research museums report in ... of the National Academy of Sciences . "Today, ... few antelope and deer are all you see," said lead ...
... aim to slow global warming through the use of ... But new research shows that the use of geoengineering ... In a symposium at the Ecological Society of America,s ... that it is potentially dangerous at the global scale, ...
Cached Biology News:Wastewater produces electricity and desalinates water 2Wastewater produces electricity and desalinates water 3Climate-caused biodiversity booms and busts in ancient plants and mammals 2Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting 2
... Peptide Antigen Design , Customer Peptide Synthesis , ... above 90%, 20 mg will be returned to customer conjugation of ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
Biology Products: